^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IAH0968

    i
    Other names: IAH0968, IAH 0968, IAH-0968
    Company:
    SunHo BioPharma
    Drug class:
    HER2 inhibitor
    Related drugs:
    4ms
    To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer (clinicaltrials.gov)
    P2/3, N=90, Not yet recruiting, SUNHO（China）BioPharmaceutical CO., Ltd.
    New P2/3 trial
    |
    IAH0968
    9ms
    Clinical Study of IAH0968 in Patients With HER2-positive Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=97, Recruiting, SUNHO（China）BioPharmaceutical CO., Ltd. | Trial completion date: Dec 2024 --> Mar 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    cisplatin • gemcitabine • IAH0968
    over1year
    IAH0968 in Combination With GC for the Treatment of HER2-Positive Unresectable Advanced/Metastatic Malignant Tumors (clinicaltrials.gov)
    P1/2, N=136, Recruiting, SUNHO（China）BioPharmaceutical CO., Ltd.
    New P1/2 trial • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    cisplatin • gemcitabine • IAH0968
    over1year
    To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2/3, N=279, Recruiting, SUNHO（China）BioPharmaceutical CO., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MSI (Microsatellite instability)
    |
    HER-2 positive • MSI-H/dMMR • KRAS wild-type • RAS wild-type • NRAS wild-type
    |
    IAH0968
    over1year
    Clinical Study of IAH0968 in Patients With HER2-positive Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=97, Recruiting, SUNHO（China）BioPharmaceutical CO., Ltd. | Not yet recruiting --> Recruiting | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Jun 2023 --> Dec 2023
    Enrollment open • Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    cisplatin • gemcitabine • IAH0968
    almost2years
    To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2/3, N=279, Not yet recruiting, SUNHO（China）BioPharmaceutical CO., Ltd.
    New P2/3 trial • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MSI (Microsatellite instability)
    |
    HER-2 positive • MSI-H/dMMR • KRAS wild-type • RAS wild-type • NRAS wild-type
    |
    IAH0968